Clinical and Diagnostic Laboratory Immunology, September 1999, p. 773-773, Vol. 6, No. 5
1071-412X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Increased Circulating Levels of Lipopolysaccharide Binding
Protein in Children with Escherichia coli O157:H7
Hemorrhagic Colitis and Hemolytic Uremic Syndrome
We report double-determinant sandwich enzyme-linked immunosorbent
assay measurements (4) of lipopolysaccharide (LPS) binding protein
(LBP) in children with uncomplicated Escherichia coli O157:H7 hemorrhagic colitis (HC) and those with O157:H7-associated hemolytic uremic syndrome (HUS). Characteristics of these children have
been previously reported (5). The analytical sensitivity of LBP
measurement was 1 ng/ml, and assay precision was 14%. Figure 1 shows that elevated levels of LBP
in plasma were noted for children with O157:H7 infections (HC versus
normal controls, P < 0.0001) and that concentrations were
increased twofold among those who developed HUS (uncomplicated HC
versus HUS, P < 0.005). Levels of circulating LPB in HUS
were comparable to those preivously noted for patients with
inflammatory bowel disease and approximately half those of patients
with sepsis (1). In our population, LBP measurements were not
correlated to the leukocyte count, interleukin 6 (IL-6), IL-8, or
soluble L-, E-, or P-selectin but were significantly correlated with
levels of IL-10 (r = 0.6, P < 0.0008), IL-1
receptor antagonist (r = 0.6; P < 0.0005), and
soluble intercellular adhesion molecular 1 (ICAM) (R = 0.4;
P < 0.02).
![]()
LETTER
Top
Letter
References

View larger version (9K):
[in a new window]
FIG. 1.
Circulating LBP concentrations in E. coli
O157:H7 infections (mean ± 95% confidence intervals [CI]). LBP
levels in plasma among 10 normal controls (NC), 15 children with
uncomplicated HC, and 10 children with HUS. Subjects were matched for
the time interval elapsed between onset of enteritis and blood sample
collection (6.5 ± 3.3 versus 6.8 ± 3.8 days, respectively [not a
significant difference]). Twofold-increased LBP concentrations were
noted for children with HUS compared to those with uncomplicated HC
(P < 0.005 [Mann-Whitney U test]). Among 9 children with
uncomplicated HC, serial LBP measurements were as follows
(means ± 95% CI): first sample, 8.7 ± 6.2 pg'ml; second sample,
4.0 ± 3.4 pg/ml (P <MEASUREME0.01). LBP concentrations
remained lower than those among children with HUS (P < 0.009).
LBP is a 60-kDa acute-phase response protein synthesized by hepatocytes
which potentiates the LPS-induced stimulation of CD14+
cells such as macrophages and neutrophils; LBP may also activate CD14
epithelial or endothelial cells through the binding
with soluble CD14 (6). Secretion of cytokines and adhesion molecules
induced by LPS results in neutrophil activation. Interestingly, we
detected an association between circulating LBP levels and
anti-inflammatory cytokines (IL-10 and IL-1 receptor antagonist) which
are classically produced by macrophages (5).
Circulating endotoxin immune complexes have been demonstrated in HUS due to shigellosis only (3). Nevertheless, the involvement of LPS in the pathophysiology of verotoxigenic E. coli infections has been hypothesized (2). Our data indicate that the acute-phase response to LPS is associated with the severity of illness during O157:H7 infections. It remains to be determined if the amount of bacterial inoculum or the effect of renal reabsorption of LBP may account for the increased levels noted during HUS. However, only one child received antibiotic therapy before blood sample collection. Consequently, our data should not have been affected by this parameter. Further studies are needed to determine the role of endotoxin in the pathophysiology of E. coli O157:H7 infections.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Caroll, S. F., R. L. Dedrick, and M. L. White. 1997. Plasma levels of lipopolysaccharide binding protein correlate with outcome in sepsis and other patients. Shock 8:101. |
| 2. | Karpman, D., H. connell, M. Svensson, A. Scheutz, P. Alm, and Svanborg. 1997. The role of lipopolysaccharides and Shiga-like toxin in a model of Escherichia coli O157:H7 infection. J. Infect. Dis. 175:611-620[Medline]. |
| 3. | Koster, F., J. Levin, L. Walker, K. S. K. Tung, R. H. Gilman, M. M. Rahaman, M. A. Majid, S. Islam, and R. C. Williams. 1979. Hemolytic-uremic syndrome after shigellosis. Relation to endotoxemia and circulating immune complexes. N. Engl. J. Med. 298:927-933[Abstract]. |
| 4. | Meszaros, K., S. Aberle, M. White, and J. B. Parent. 1995. Immunoreactivity and bioactivity of lipopolysaqccharide-binding protein in normal and heat-inactivated sera. Infect. Immun. 63:363-365[Abstract]. |
| 5. | Proulx, F., C. Litalien, J. P. Turgeon, M. M. Mariscalco, and E. Seidman. 1998. Inflammatory mediators in hemorrhagic colitis and hemolytic uremic syndrome. Pediatr. Inf. dis. J. 17:899-904. [Medline] |
| 6. |
Write, S. D.
1991.
CD14 and immune response to lipopolysaccharide.
Science
252:1321-1322 |
|
François Proulx Ernest Seidman Department of Pediatrics Sainte-Justine Hospital University of Montreal Canada | |||||
|
Michelle M. Mariscalco Department of Pediatrics Texas Children's Hospital Baylor College of Medicine Houston, Texas | |||||
|
Kelly Lee Stephen Caroll XOMA Corporation Berkeley, California |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. | Infect. Immun. |
|---|---|---|
| J. Clin. Microbiol. | J. Virol. | ALL ASM JOURNALS |